Biological evaluation of matrix metalloproteinase inhibitors, 18 May 1995, New York.
Pratta
M A
MA
DuPont Merck Pharmaceutical Company, Inflammation Research Division, Wilmington, DE 19880, USA.
D000818:Animals; D006801:Humans; D006877:Hydroxamic Acids; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors*; D010003:Osteoarthritis / Q000188:drug therapy* / Q000378:metabolism; D011480:Protease Inhibitors / Q000494:pharmacology*; D011509:Proteoglycans / Q000378:metabolism; D011719:Pyrazines; D013449:Sulfonamides
C097658:CGS 27023A; D006877:Hydroxamic Acids; D011480:Protease Inhibitors; D011509:Proteoglycans; D011719:Pyrazines; D013449:Sulfonamides; D008666:Metalloendopeptidases